David Mutch

21PUBLICATIONS
122CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsCancer geneticsEpigenetics (incl. genome methylation and epigenomics)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Aug 29, 2026
The new (version 9) American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) staging protocol for carcinoma of the vulva.

|Jul 22, 2025
Multiomic Characterization of Pre- and Post-Neoadjuvant Chemotherapy-Treated Ovarian Cancer Reveals Mediators of Tumorigenesis and Chemotherapy Response.

Mark C Valentine, Mary M Mullen, Emilee N Kotnik

|Feb 26, 2025
Enhancing Progestin Therapy with a Glucagon-Like Peptide 1 Agonist for the Conservative Management of Endometrial Cancer.

Andrea R Hagemann, Ian S Hagemann, David G Mutch

|Dec 19, 2024
Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma.

Daniela E Matei, Danielle M Enserro, Marcus E Randall

|May 22, 2024
Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study.

Charles N Landen, Ronald J Buckanovich, Michael W Sill

|Jan 30, 2024
Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer.

David Mutch, Athina Voulgari, Xian Marissa Chen

Pageof 4

Frequent Collaborators

4 joint publications

Matthew A Powell

4 joint publications

Ian S Hagemann

4 joint publications

Krishnansu S Tewari

3 joint publications

Dineo Khabele